Odyssey Group Intl (OTC:ODYY) Stock, Quote.Headers.trade-ideas

Odyssey Group International Inc is a company focused on developing life-saving medical products, Odyssey's goal is to create, acquire and accumulate distinct assets, intellectual property, and technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity.

News

Intraday Update

Markets

Movers

Trading Ideas

ABBRF

ACGL

ADBE

ADSK

ADVM

AEHR

AEMMY

AFGC

AGNC

AMRC

AMWD

AMXEF

ANSS

ARCAY

ARCVF

ARDC

ARNC

ASHTY

ATVI

AVXL

AZMTF

AZRE

BABYF

BLDP

BLDR

BRSGF

BWXT

CACI

CALA

CCYC

CDNS

CELH

CEVA

CGEN

CHDN

CHTR

CLGX

CLPBY

CNNE

COST

CRMT

CROL

CSLLY

CTAS

CVNA

CWEN

CWEN-A

DBOEY

DGIF

DNNGY

DOCU

DOGEF

DOOO

DOOR

Stocks That Hit 52-Week Highs On Wednesday

AAON

AAXN

ABBV

ACIA

ACLS

ADUS

AGRX

AGYS

AIQUY

AJRD

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALKEF

ALPMY

AMED

AMZN

APAM

APTO

ARCC

ARES

ARKR

ASHTF

ASML

ASMLF

ASND

ATRC

BFAM

Brighthouse Financial, Inc. - Common Stock

BILI

BILL

BNTGF

BPUZF

BRLXF

BTCY

BURL

BWMC

CBRE

CCXI

CFBK

CHCT

CHGCY

CNRMF

CPWHF

Stocks That Hit 52-Week Highs On Tuesday

AHCO

ALEC

ALSWF

AMRR

APPF

BBSRF

BCBHF

BYCBF

CAPL

CASH

CGUD

CLNXF

CNSUF

CRUS

CYDY

DDOG

EDPFY

ELYGF

ENLAY

EVRG

FBHS

FCPT

FJTSF

FLXT

GLPI

GPTRF

GSHD

GVDNY

IBDRY

INGIF

IRVRF

LAUR

LLNW

LRCX

LTCCF

LZAGF

MAPIF

MBKL

MDLZ

Blackrock Muniyield Michigan Quality Fund

MLNX

MSCI

MSFT

Blackrock Muniholdings California Quality Fund

Blackrock Muniyield New York Quality Fund

NAUH

NDAQ

Nuveen Insured Tax-Free Advantage Municipal Fund

NGGTF

Nuveen Insured California Tax-Free Advantage Municipal Fund

NYMX

ODYY

OSSPF

PAYC

PCYO

Stocks That Hit 52-Week Highs On Thursday

ODYSSEY GROUP INTL INC by Odyssey Group Intl Inc.

Odyssey Group International Inc

RepaymenrtPebblebrook Hotel Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) (the "Company") today announced that its operating partnership, Pebblebrook Hotel, L.P. (the "Operating Partnership"), and a wholly owned subsidiary of the Operating Partnership, PEB Finance Corp.(together with the Operating Partnership, the "Issuers"), intend to offer, in a private placement, subject to market conditions and other factors, $350 million aggregate principal amount of senior notes due 2029 (the "Notes"). The Notes will be senior unsecured obligations of the Issuers and will initially be fully and unconditionally guaranteed by the Company and the Operating Partnership's subsidiaries that guarantee the existing credit facilities of the Operating Partnership. The Operating Partnership intends to use the net proceeds from the offering as follows: (i) with at least $253.0 million, to pay down in whole or in part one or more of the Operating Partnership's unsecured term loans and (ii) with the balance, which may be up to $87.4 million, to pay down part of one or more of the Operating Partnership's other unsecured term loans and/or repurchase a portion of the convertible senior notes of the Company.
&nbsp;

Offerings

Pebblebrook Hotel Trust To Raise $350M Via Proposed Offering of Senior Notes For Debt Repayment

Lottery.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>, LTRYW)))) ("Lottery.com" or the "Company") is pleased to announce that Sports.com, a global leader in digital sports entertainment, has significantly expanded its geographic reach, launching its platform and content in new markets across Asia. This expansion is part of Sports.com's ongoing commitment to delivering premium sports content to millions of potential fans worldwide, further extending its commercial reach beyond Africa and the Middle East. &nbsp;
With increasing global demand for high-quality sports entertainment, particularly for core sporting events, Sports.com continues to lead the industry. By partnering with Forest Interactive, the platform is now live in Malaysia, the UAE, Saudi Arabia, and the broader MENA region.

Global

LTRY

Sports.com Expands Its Geographic Reach, Launching Its Platform And Content In New Markets Across Asia

Deutsche Bank analyst Bryan Keane maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Buy and raises the price target from $74 to $94.

Price Target

Analyst Ratings

PYPL

Deutsche Bank Maintains Buy on PayPal Holdings, Raises Price Target to $94

WIIM

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Maxeon shares are trading lower after the company said it is proceeding with an approved reverse stock split.

BMO Capital analyst Daniel Jester initiates coverage on OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) with a Outperform rating and announces Price Target of $38.

Initiation

BMO Capital Initiates Coverage On OneStream with Outperform Rating, Announces Price Target of $38

General Motors shares are trading lower after Bernstein downgraded the stock from Outperform to Market Perform.

Signing Day Sports shares are trading higher after the company announced that it provided an update regarding its financial position and its plans to acquire Dear Cashmere Group Holding Company, doing business as Swifty Global.

ULTA

Ulta Beauty shares are trading lower after TD Cowen downgraded the stock to Hold.

Baird analyst David Koning maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Outperform and raises the price target from $186 to $200.

Baird Maintains Outperform on Fiserv, Raises Price Target to $200

Wheels Up shares are trading higher after the company announced that approximately 97.2% of lead investor shares will remain subject to a lock-up restriction until September 20, 2025.

Baird analyst Peter Arment maintains Kratos Defense &amp; Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) with a Outperform and raises the price target from $22 to $35.

KTOS

Baird Maintains Outperform on Kratos Defense & Security, Raises Price Target to $35

BDTX

Black Diamond Therapeutics shares are trading higher after the company announced initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor-mutant non-small cell lung cancer.

In a recent turn of events, the United States has directly cautioned Israel against escalating hostilities with Hezbollah, as the two sides engage in intense cross-border exchanges. The U.S. has urged Israel to seek diplomatic solutions, emphasizing the potential risks of a full-scale land war.
What Happened: On Sunday, Israeli forces and Hezbollah militants clashed in some of the most severe confrontations since Oct. 7, Financial Times <a href="https://www.ft.com/content/2bb03f05-c3d5-4f3f-99e3-56f541f51769">reported</a> on Monday. The escalating violence has raised concerns about the situation spiraling into a full-scale war.
John Kirby, a spokesperson for the U.S. National Security Council, cautioned Israel against escalating the conflict. He stated that there are &#8220;better ways&#8221; to ensure the safety of Israeli citizens than through war or further escalation. President Joe Biden assured that his administration would do everything possible to prevent a wider war.
Despite international calls for de-escalation, Israeli Prime Minister Benjamin Netanyahu has pledged to maintain military pressure on Hezbollah. The situation has become increasingly tense, with the recent hostilities resulting in a significant rise in casualties.
See Also: <a href="https://www.benzinga.com/news/24/09/40970828/data-scientists-election-prediction-kamala-harris-receives-historic-endorsement-from-magazine-elon-m?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Data Scientist&#8217;s Election Prediction, Kamala Harris Receives Historic Endorsement From Magazine, Elon Musk Suggests Warren Buffett Is Preparing For A Harris Win And More: Top Political Update This Week</a>
On Monday, Israeli airstrikes in Lebanon led to 30 deaths and over 300 injuries, as per CNN. This escalation follows a series of events, including Hezbollah&#8217;s rocket attacks on Israel and the detonation of the group&#8217;s communication devices, which Hezbollah blames on Israel. The recent violence has led to fears of a potential full-scale war.
Why It Matters: The recent violence adds to the <a href="https://www.benzinga.com/news/24/09/40924166/hezbollah-hit-in-new-round-of-explosions-across-lebanon-casualties-climb">already tense situation</a> in the region. Just last week, Lebanon experienced a second wave of deadly explosions targeting Hezbollah operatives, following a massive wave of pager explosions that killed 12 people and injured nearly 2,800 more. The second round of explosions killed at least nine people and injured over 300, further exacerbating the situation in Lebanon.
Meanwhile, U.S. Senator Lindsey Graham has called for a new <a href="https://www.benzinga.com/news/24/09/40973072/lindsey-graham-says-either-saudi-arabia-recogonizes-israel-or-tel-aviv-targets-tehran-we-need-game-c">approach to Middle East policy,</a> advocating for either a &#8220;game-changing peace&#8221; or a &#8220;game-changing military strategy.&#8221; Graham suggested that a significant shift in strategy is needed, either through Saudi Arabia recognizing Israel, or Israel taking military action against Iran.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo by Ilin Sergey on Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

General

US Warns Israel Against Opening A Full-Blown War Against Hezbollah As Air Strikes Kill 30 In Lebanon

Monday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator&#8217;s choice of chemotherapy.
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.html" rel="noreferrer noopener">study</a> did not achieve statistical significance in the final overall survival (OS) analysis in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy.
The study previously met the dual primary endpoint of progression-free survival.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40793946/astrazeneca-ceo-pascal-soriot-updates-on-chinese-compliance-probe-and-lung-cancer-drug-trial-resu" rel="noreferrer noopener">AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results</a>.
An improvement in patient-reported outcomes was also seen.
The safety profile of datopotamab deruxtecan was consistent with that observed in the previous analysis, including lower rates of Grade 3 or higher treatment-related adverse events compared to chemotherapy, and no new safety concerns were identified.
All-grade interstitial lung disease (ILD) rates remained low, and no new Grade 3 or higher ILD events were observed.
With multiple antibody-drug conjugates (ADCs) approved during the trial, including&nbsp;Enhertu (trastuzumab deruxtecan), subsequent treatment following patients&#8217; disease progression or treatment discontinuation is likely to have affected survival results.
Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd ADC discovered by Daiichi Sankyo Ltd&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSKYF#OTC">DSKYF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) and being jointly developed by AstraZeneca and Daiichi Sankyo.
Earlier this month, AstraZeneca&nbsp;shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with at least&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40791315/astrazenecas-investigational-cancer-drug-disappoints-in-late-stage-lung-cancer-trial" rel="noreferrer noopener">one prior line of therapy</a>.
In the overall trial population, OS results numerically favored datopotamab deruxtecan compared to docetaxel (12.9 vs. 11.8 months) but did not reach statistical significance.
Friday, the FDA <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html" rel="noreferrer noopener">approved</a> AstraZeneca&#8217;s FluMist as the only self-administered influenza vaccine.&nbsp;
FluMist, a needle-free nasal spray, was approved for self-administration by adults up to 49 years of age or for parent/caregiver administration to individuals 2-17 years of age.
Once available, individuals 18 and older can have FluMist delivered directly to their homes via FluMist Home.
Price Action: AZN stock is down 1.86% at $76.92 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" target="_blank" rel="noreferrer noopener">US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth&#8217;s Pharmacy Benefit Managers For Inflating Insulin Prices</a>.</li>
</ul>
Image by Robert Way via Shutterstock

Biotech

Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Odyssey Group Intl

Odyssey Group Intl (ODYY) Forecast

Odyssey Group Intl (OTC:ODYY) Stock, Quote.Headers.trade-ideas